mutation class

Small Mutation

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

2 sites for NCT02645149

ALK Fusion, +19 more biomarkers

Melanoma, +1 more condition

ceritinib, +4 more drugs

targeted therapy

Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

1 site for NCT04708054

ARAF Mutation, +47 more biomarkers

Acute Myeloid Leukemia, +2 more conditions

busulfan, +5 more drugs

cellular therapy, +1 more type

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

51 sites for NCT03190915

CBL Loss, +8 more biomarkers

Juvenile Myelomonocytic Leukemia, +1 more condition

trametinib

targeted therapy

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

1 site for NCT05168904

BRAF Mutation, +6 more biomarkers

Acute Myeloid Leukemia, +3 more conditions

CYC065

targeted therapy

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

10 sites for NCT03297606

ABL1 Fusion, +98 more biomarkers

B-Cell Non-Hodgkin Lymphoma, +2 more conditions

axitinib, +15 more drugs

immunotherapy, +1 more type